MedTrace Logo

Oral vs Intravenous Diltiazem for Rapid Atrial Fibrillation/Flutter Trial

NCT03472495 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2023-03-01

Study results available
· View outcomes & findings →

Summary

The primary objective of this study is to compare the incidence of rate control (defined as: HR \<110 beats/min or conversion to sinus rhythm) at 2 hours after medication administration between oral immediate release diltiazem and intravenous continuous infusion diltiazem.

Conditions

  • Atrial Fibrillation and Flutter

Interventions

DRUG

Diltiazem Oral Product

Diltiazem Immediate Release 60 MG PO Q6H (30 MG PO Q6H if patient is \<60 kg)

DRUG

Diltiazem Injectable Product

Diltiazem Continuous Infusion Titrated

Sponsors & Collaborators

  • Virginia Commonwealth University

    lead OTHER

Principal Investigators

  • Tammy T Nguyen, PharmD, BCPS · Virginia Commonwealth University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-01
Primary Completion
2021-03-21
Completion
2021-03-21
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03472495 on ClinicalTrials.gov